Liglipol Tablet contains Tacrolimus 5 mg, an immunosuppressive agent primarily used to prevent organ transplant rejection and to treat certain autoimmune conditions. Tacrolimus acts by inhibiting calcineurin, thereby suppressing T-lymphocyte activation and reducing immune response. This mechanism helps in minimizing the risk of graft rejection following kidney, liver, or heart transplantation. Additionally, Tacrolimus is utilized in managing severe atopic dermatitis and other inflammatory skin disorders when conventional therapies are inadequate. Liglipol Tablet should be administered under strict medical supervision, with dosage tailored according to the patient’s clinical condition and response. Regular monitoring of blood levels, renal function, liver enzymes, and blood pressure is essential due to the drug’s narrow therapeutic index and potential for nephrotoxicity, neurotoxicity, and other adverse effects. Common side effects include tremors, headache, gastrointestinal disturbances, and increased susceptibility to infections. Patients should be advised to avoid grapefruit juice and other CYP3A4 inhibitors, as these may increase Tacrolimus blood concentrations, heightening toxicity risk. Liglipol Tablet is contraindicated in patients with hypersensitivity to Tacrolimus or any formulation components. Proper adherence to prescribed regimens and routine follow-up are critical to optimizing therapeutic outcomes and minimizing complications associated with Tacrolimus therapy.